214 related articles for article (PubMed ID: 26970171)
1. Down-regulation of EZH2 expression in myelodysplastic syndromes.
Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
[TBL] [Abstract][Full Text] [Related]
2. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
4. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
[TBL] [Abstract][Full Text] [Related]
5. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.
Wei Y; Chen R; Dimicoli S; Bueso-Ramos C; Neuberg D; Pierce S; Wang H; Yang H; Jia Y; Zheng H; Fang Z; Nguyen M; Ganan-Gomez I; Ebert B; Levine R; Kantarjian H; Garcia-Manero G
Leukemia; 2013 Nov; 27(11):2177-86. PubMed ID: 23538751
[TBL] [Abstract][Full Text] [Related]
6. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
7. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
Lee SW; Park DY; Kim MY; Kang C
Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Retinal Development via the Epigenetic Modification of Histone H3.
Watanabe S; Murakami A
Adv Exp Med Biol; 2016; 854():635-41. PubMed ID: 26427469
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
Nikoloski G; Langemeijer SM; Kuiper RP; Knops R; Massop M; Tönnissen ER; van der Heijden A; Scheele TN; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
Nat Genet; 2010 Aug; 42(8):665-7. PubMed ID: 20601954
[TBL] [Abstract][Full Text] [Related]
10. JMJD3 as an epigenetic regulator in development and disease.
Burchfield JS; Li Q; Wang HY; Wang RF
Int J Biochem Cell Biol; 2015 Oct; 67():148-57. PubMed ID: 26193001
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
[TBL] [Abstract][Full Text] [Related]
12. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
13. Expression and significance of histone H3K27 demethylases in renal cell carcinoma.
Shen Y; Guo X; Wang Y; Qiu W; Chang Y; Zhang A; Duan X
BMC Cancer; 2012 Oct; 12():470. PubMed ID: 23057811
[TBL] [Abstract][Full Text] [Related]
14. The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer.
Daures M; Ngollo M; Judes G; Rifaï K; Kemeny JL; Penault-Llorca F; Bignon YJ; Guy L; Bernard-Gallon D
OMICS; 2016 Feb; 20(2):123-5. PubMed ID: 26871869
[No Abstract] [Full Text] [Related]
15. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Expression of
de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
[TBL] [Abstract][Full Text] [Related]
17. Histone-modifying genes as biomarkers in hepatocellular carcinoma.
Hung SY; Lin HH; Yeh KT; Chang JG
Int J Clin Exp Pathol; 2014; 7(5):2496-507. PubMed ID: 24966962
[TBL] [Abstract][Full Text] [Related]
18. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
Wang JY; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
[TBL] [Abstract][Full Text] [Related]
19. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.
Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C
Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902
[TBL] [Abstract][Full Text] [Related]
20. The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
Xu F; Li X
Expert Rev Hematol; 2012 Apr; 5(2):177-85. PubMed ID: 22475286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]